Does Rallies show 13F holders for RCUS?

Yes. Rallies tracks hedge fund and 13F ownership data for RCUS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is RCUS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RCUS. It does not provide personalized investment advice.

RCUS (Arcus Biosciences, Inc.) Stock Analysis - Hedge Fund Holdings

Arcus Biosciences, Inc. (RCUS) is a publicly traded Healthcare sector company. As of May 21, 2026, RCUS trades at $23.82 with a market cap of $2.94B and a P/E ratio of -7.37. RCUS moved +4.48% today. Year to date, RCUS is +9.05%; over the trailing twelve months it is +167.64%. Its 52-week range spans $6.50 to $28.72. Analyst consensus is strong buy with an average price target of $35.89. Rallies surfaces RCUS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns RCUS stock?

Hedge funds tracked by Rallies that own RCUS include Orbimed Advisors, Panagora Asset, and Mangrove Partners. The latest tracked quarter is Dec 31, 2023. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Arcus Biosciences, Inc..

RCUS Key Metrics

Key financial metrics for RCUS
Metric	Value
Price	$23.82
Market Cap	$2.94B
P/E Ratio	-7.37
EPS	$-3.19
Dividend Yield	0.00%
52-Week High	$28.72
52-Week Low	$6.50
Volume	109
Avg Volume	0
Revenue (TTM)	$236.00M
Net Income	$-369.00M
Gross Margin	0.00%

Top Hedge Funds Holding RCUS

Orbimed Advisors holds 117.00K shares of RCUS, changed +0.00% as of Dec 31, 2023.
Panagora Asset holds 112.83K shares of RCUS, changed -54.06% as of Sep 30, 2024.
Mangrove Partners holds 84.00K shares of RCUS, changed +0.00% as of Mar 31, 2025.

Latest RCUS News

Arcus Casdatifan Shows 45% ORR, 15.1-Month PFS and $1B Cash; PEAK-1 Enrollment Underway — Feb 28, 2026
Arcus Biosciences Shares Surge 88.2% While 2026 Loss Estimate Narrows — Feb 27, 2026
Arcus Biosciences Ends Q4 with $400M+ Cash, Prepares for Phase II Readouts — Feb 26, 2026
Arcus Biosciences Reports Over 12-Month PFS in Late-Line Kidney Cancer — Feb 23, 2026
Arcus Biosciences Price Target Cut to $23 Over Welireg Concerns; Goldman Sachs Sees $28 — Feb 19, 2026

Recent RCUS Insider Trades

Jaen Juan C. sold 29.67K (~$633.16K) on Jan 5, 2026.
Jaen Juan C. sold 2.05K (~$45.86K) on Jan 5, 2026.
Jaen Juan C. sold 100 (~$2.32K) on Jan 5, 2026.

RCUS Analyst Consensus

10 analysts cover RCUS: 0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.89.

Common questions about RCUS

Who owns RCUS stock?: Hedge funds tracked by Rallies that own RCUS include Orbimed Advisors, Panagora Asset, and Mangrove Partners. The latest tracked quarter is Dec 31, 2023. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Arcus Biosciences, Inc..
Does Rallies show 13F holders for RCUS?: Yes. Rallies tracks hedge fund and 13F ownership data for RCUS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is RCUS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RCUS. It does not provide personalized investment advice.